William G. Kaelin

68.2k total citations · 55 hit papers
246 papers, 50.2k citations indexed

About

William G. Kaelin is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, William G. Kaelin has authored 246 papers receiving a total of 50.2k indexed citations (citations by other indexed papers that have themselves been cited), including 181 papers in Molecular Biology, 134 papers in Cancer Research and 90 papers in Oncology. Recurrent topics in William G. Kaelin's work include Cancer, Hypoxia, and Metabolism (124 papers), Cancer-related Molecular Pathways (72 papers) and Epigenetics and DNA Methylation (47 papers). William G. Kaelin is often cited by papers focused on Cancer, Hypoxia, and Metabolism (124 papers), Cancer-related Molecular Pathways (72 papers) and Epigenetics and DNA Methylation (47 papers). William G. Kaelin collaborates with scholars based in United States, United Kingdom and Canada. William G. Kaelin's co-authors include Peter J. Ratcliffe, Mircea Ivan, Keiichi Kondo, Michael Ohh, Othon Iliopoulos, David M. Livingston, Haifeng Yang, William Y. Kim, William R. Sellers and Nikola P. Pavletich and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

William G. Kaelin

243 papers receiving 49.4k citations

Hit Papers

HIFα Targeted for VHL-Med... 1991 2026 2002 2014 2001 2008 2000 2013 2004 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
    2001 3.9k citations Mircea Ivan, Keiichi Kondo et al. Science profile →
  2. Oxygen Sensing by Metazoans: The Central Role of the HIF Hydroxylase Pathway
    2008 2.5k citations William G. Kaelin et al. Molecular Cell profile →
  3. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein
    2000 1.3k citations Michael Ohh, Mircea Ivan et al. profile →
  4. The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
    2013 1.1k citations Gang Lu, Richard E. Middleton et al. Science profile →
  5. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex
    2004 1.1k citations William G. Kaelin et al. profile →
  6. The Concept of Synthetic Lethality in the Context of Anticancer Therapy
    2005 1.0k citations William G. Kaelin profile →
  7. p73 is a human p53-related protein that can induce apoptosis
    1997 835 citations William G. Kaelin et al. Nature profile →
  8. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage
    1999 785 citations William G. Kaelin et al. Nature profile →
  9. Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties
    1992 777 citations William G. Kaelin, William R. Sellers et al. profile →
  10. Role ofVHLGene Mutation in Human Cancer
    2004 727 citations William Y. Kim, William G. Kaelin profile →
  11. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.
    1996 713 citations William G. Kaelin et al. Proceedings of the National Academy of Sciences profile →
  12. Structure of the VHL-ElonginC-ElonginB Complex: Implications for VHL Tumor Suppressor Function
    1999 689 citations William G. Kaelin et al. Science profile →
  13. Rbx1, a Component of the VHL Tumor Suppressor Complex and SCF Ubiquitin Ligase
    1999 661 citations William G. Kaelin et al. Science profile →
  14. E2F-1 Functions in Mice to Promote Apoptosis and Suppress Proliferation
    1996 661 citations William G. Kaelin et al. profile →
  15. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis.
    1994 658 citations William G. Kaelin et al. Proceedings of the National Academy of Sciences profile →
  16. Influence of Metabolism on Epigenetics and Disease
    2013 654 citations William G. Kaelin et al. profile →
  17. Molecular basis of the VHL hereditary cancer syndrome
    2002 637 citations William G. Kaelin profile →
  18. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
    2002 635 citations Keiichi Kondo, Mirna Lechpammer et al. profile →
  19. Structure of an HIF-1α-pVHL Complex: Hydroxyproline Recognition in Signaling
    2002 619 citations Mircea Ivan, William G. Kaelin et al. Science profile →
  20. Role for the p53 homologue p73 in E2F-1-induced apoptosis
    2000 592 citations William G. Kaelin et al. Nature profile →
  21. Tumour suppression by the human von Hippel-Lindau gene product
    1995 577 citations William G. Kaelin et al. Nature Medicine profile →
  22. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
    2012 566 citations Peppi Koivunen, Sung-Woo Lee et al. Nature profile →
  23. The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer
    2008 549 citations William G. Kaelin profile →
  24. Binding of the von Hippel-Lindau Tumor Suppressor Protein to Elongin B and C
    1995 539 citations William G. Kaelin et al. Science profile →
  25. ( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
    2013 533 citations Ryan Looper, Peppi Koivunen et al. Science profile →
  26. The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families
    1998 507 citations William G. Kaelin et al. profile →
  27. Identification of cellular proteins that can interact specifically with the T/ElA-binding region of the retinoblastoma gene product
    1991 496 citations William G. Kaelin et al. profile →
  28. Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth
    2003 481 citations Keiichi Kondo, William Y. Kim et al. PLoS Biology profile →
  29. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor
    2002 478 citations Mircea Ivan, Volkmar Günzler et al. Proceedings of the National Academy of Sciences profile →
  30. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour
    2000 442 citations William G. Kaelin et al. profile →
  31. Suppression of tumor growth through disruption of hypoxia-inducible transcription
    2000 436 citations Andrew L. Kung, Jeffery M. Klco et al. Nature Medicine profile →
  32. TSC2 regulates VEGF through mTOR-dependent and -independent pathways
    2003 429 citations William R. Sellers, William G. Kaelin et al. profile →
  33. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
    2013 424 citations William G. Kaelin et al. profile →
  34. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: Developmental culling and cancer
    2005 417 citations Sung-Woo Lee, William G. Kaelin et al. profile →
  35. Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex
    2001 410 citations William G. Kaelin et al. profile →
  36. Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex
    2004 400 citations William G. Kaelin et al. Nature profile →
  37. von Hippel-Lindau Disease
    1997 395 citations William G. Kaelin et al. profile →
  38. The von Hippel-Lindau Tumor Suppressor Protein Is Required for Proper Assembly of an Extracellular Fibronectin Matrix
    1998 395 citations Michael Ohh, William G. Kaelin et al. Molecular Cell profile →
  39. PROLINE HYDROXYLATION AND GENE EXPRESSION
    2005 389 citations William G. Kaelin profile →
  40. Identification of a growth suppression domain within the retinoblastoma gene product.
    1992 379 citations William G. Kaelin et al. profile →
  41. The T/E1A-binding domain of the retinoblastoma product can interact selectively with a sequence-specific DNA-binding protein
    1991 364 citations William G. Kaelin et al. profile →
  42. Chemosensitivity linked to p73 function
    2003 345 citations Keiichi Kondo, William G. Kaelin et al. profile →
  43. The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase
    2005 337 citations William G. Kaelin et al. profile →
  44. On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models
    2016 336 citations Hyejin Cho, Xinlin Du et al. Nature profile →
  45. The Retinoblastoma Binding Protein RBP2 Is an H3K4 Demethylase
    2007 336 citations William G. Kaelin et al. profile →
  46. Identification of a Cyclin-cdk2 Recognition Motif Present in Substrates and p21-Like Cyclin-Dependent Kinase Inhibitors
    1996 323 citations William R. Sellers, William G. Kaelin et al. profile →
  47. Genetic and Functional Studies Implicate HIF1 α as a 14q Kidney Cancer Suppressor Gene
    2011 313 citations Chuan Shen, Rameen Beroukhim et al. Cancer Discovery profile →
  48. Patterns of Gene Expression and Copy-Number Alterations in von-Hippel Lindau Disease-Associated and Sporadic Clear Cell Carcinoma of the Kidney
    2009 310 citations Rameen Beroukhim, Arianna Di Napoli et al. Cancer Research profile →
  49. Targeting the HIF2–VEGF axis in renal cell carcinoma
    2020 299 citations Toni K. Choueiri, William G. Kaelin Nature Medicine profile →
  50. The VHL/HIF axis in clear cell renal carcinoma
    2012 294 citations Chuan Shen, William G. Kaelin profile →
  51. E2F-1-mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product.
    1993 286 citations William G. Kaelin et al. Proceedings of the National Academy of Sciences profile →
  52. Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate
    2019 280 citations Abhishek A. Chakraborty, Rebecca B. Jennings et al. Science profile →
  53. Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes
    2015 248 citations William G. Kaelin, Peppi Koivunen et al. profile →
  54. The EGLN-HIF O 2 -Sensing System: Multiple Inputs and Feedbacks
    2017 198 citations Mircea Ivan, William G. Kaelin Molecular Cell profile →
  55. Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine
    2016 193 citations Peppi Koivunen, Qing Zhang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
William G. Kaelin United States 117 35.6k 22.6k 14.8k 6.0k 6.0k 246 50.2k
Chi V. Dang United States 100 38.9k 1.1× 24.2k 1.1× 9.5k 0.6× 3.3k 0.6× 3.1k 0.5× 310 53.3k
Victor E. Velculescu United States 83 34.5k 1.0× 17.0k 0.8× 20.4k 1.4× 6.4k 1.1× 4.9k 0.8× 184 54.3k
Amato J. Giaccia United States 103 23.1k 0.6× 17.4k 0.8× 10.8k 0.7× 4.2k 0.7× 2.6k 0.4× 350 40.3k
David Sidransky United States 121 40.0k 1.1× 17.1k 0.8× 25.6k 1.7× 9.6k 1.6× 5.2k 0.9× 576 66.1k
Richard G. Pestell United States 124 33.3k 0.9× 13.5k 0.6× 15.2k 1.0× 3.7k 0.6× 4.7k 0.8× 465 49.9k
Eric R. Fearon United States 82 23.8k 0.7× 12.5k 0.6× 20.8k 1.4× 4.3k 0.7× 5.4k 0.9× 191 45.9k
Scott W. Lowe United States 123 50.1k 1.4× 16.9k 0.7× 23.0k 1.6× 3.6k 0.6× 4.2k 0.7× 325 69.6k
Carlos Cordon‐Cardo United States 129 41.4k 1.2× 12.8k 0.6× 22.8k 1.5× 11.0k 1.8× 4.0k 0.7× 564 68.1k
Mien‐Chie Hung United States 138 43.4k 1.2× 13.8k 0.6× 28.0k 1.9× 7.7k 1.3× 5.1k 0.9× 745 67.2k
Kornélia Polyák United States 85 30.3k 0.9× 14.8k 0.7× 26.6k 1.8× 4.6k 0.8× 3.5k 0.6× 202 49.8k

Countries citing papers authored by William G. Kaelin

Since Specialization
Citations

This map shows the geographic impact of William G. Kaelin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William G. Kaelin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William G. Kaelin more than expected).

Fields of papers citing papers by William G. Kaelin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William G. Kaelin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William G. Kaelin. The network helps show where William G. Kaelin may publish in the future.

Co-authorship network of co-authors of William G. Kaelin

This figure shows the co-authorship network connecting the top 25 collaborators of William G. Kaelin. A scholar is included among the top collaborators of William G. Kaelin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William G. Kaelin. William G. Kaelin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shirole, Nitin H., Yenarae Lee, Amy Goodale, et al.. (2025). Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer. Cancer Discovery. 15(7). 1484–1504. 2 indexed citations
2.
Abu‐Remaileh, Muhannad, Nicole S. Persky, Yenarae Lee, David E. Root, & William G. Kaelin. (2024). Total loss of VHL gene function impairs neuroendocrine cancer cell fitness due to excessive HIF2α activity. Proceedings of the National Academy of Sciences. 121(40). e2410356121–e2410356121. 4 indexed citations
3.
Wyant, Gregory A., Wenyu Yu, Mossab Y. Saeed, et al.. (2022). Mitochondrial remodeling and ischemic protection by G protein–coupled receptor 35 agonists. Science. 377(6606). 621–629. 70 indexed citations
4.
Choueiri, Toni K. & William G. Kaelin. (2020). Targeting the HIF2–VEGF axis in renal cell carcinoma. Nature Medicine. 26(10). 1519–1530. 299 indexed citations breakdown →
5.
Nicholson, Hilary E., Zeshan Tariq, Benjamin E. Housden, et al.. (2019). HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species. Science Signaling. 12(601). 57 indexed citations
6.
Ivan, Mircea & William G. Kaelin. (2017). The EGLN-HIF O 2 -Sensing System: Multiple Inputs and Feedbacks. Molecular Cell. 66(6). 772–779. 198 indexed citations breakdown →
7.
Cho, Hyejin, Xinlin Du, James P. Rizzi, et al.. (2016). On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models. Nature. 539(7627). 107–111. 336 indexed citations breakdown →
8.
Zhang, Jing, Chengyang Wang, Xi Chen, et al.. (2015). EglN2 associates with the NRF 1‐ PGC 1α complex and controls mitochondrial function in breast cancer. The EMBO Journal. 34(23). 2953–2970. 59 indexed citations
9.
Andronesi, Ovidiu C., Franziska Loebel, Wolfgang Bogner, et al.. (2015). Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. Clinical Cancer Research. 22(7). 1632–1641. 116 indexed citations
10.
Lu, Gang, Richard E. Middleton, Huahang Sun, et al.. (2013). The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins. Science. 343(6168). 305–309. 1108 indexed citations breakdown →
11.
Looper, Ryan, Peppi Koivunen, Sung-Woo Lee, et al.. (2013). ( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible. Science. 339(6127). 1621–1625. 533 indexed citations breakdown →
12.
Shen, Chuan, Rameen Beroukhim, Steven E. Schumacher, et al.. (2011). Genetic and Functional Studies Implicate HIF1 α as a 14q Kidney Cancer Suppressor Gene. Cancer Discovery. 1(3). 222–235. 313 indexed citations breakdown →
13.
Moslehi, Javid J., Yoji Andrew Minamishima, Jianru Shi, et al.. (2010). Loss of Hypoxia-Inducible Factor Prolyl Hydroxylase Activity in Cardiomyocytes Phenocopies Ischemic Cardiomyopathy. Circulation. 122(10). 1004–1016. 138 indexed citations
14.
Beroukhim, Rameen, Arianna Di Napoli, Kirsten D. Mertz, et al.. (2009). Patterns of Gene Expression and Copy-Number Alterations in von-Hippel Lindau Disease-Associated and Sporadic Clear Cell Carcinoma of the Kidney. Cancer Research. 69(11). 4674–4681. 310 indexed citations breakdown →
15.
Kim, William Y., Samanthi A. Perera, Bing Zhou, et al.. (2009). HIF2α cooperates with RAS to promote lung tumorigenesis in mice. Journal of Clinical Investigation. 119(8). 2160–2170. 120 indexed citations
16.
Kim, William Y., Michal Safran, Benjamin L. Ebert, et al.. (2006). Failure to prolyl hydroxylate hypoxia‐inducible factor α phenocopies VHL inactivation in vivo. The EMBO Journal. 25(19). 4650–4662. 193 indexed citations
17.
Safran, Michal, William Y. Kim, Fionnuala O’Connell, et al.. (2005). Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: Assessment of an oral agent that stimulates erythropoietin production. Proceedings of the National Academy of Sciences. 103(1). 105–110. 238 indexed citations
18.
Olenyuk, Bogdan, Guo‐Jun Zhang, Jeffery M. Klco, et al.. (2004). Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proceedings of the National Academy of Sciences. 101(48). 16768–16773. 181 indexed citations
19.
Kondo, Keiichi, William Y. Kim, Mirna Lechpammer, & William G. Kaelin. (2003). Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth. PLoS Biology. 1(3). e83–e83. 481 indexed citations breakdown →
20.
Ohh, Michael, et al.. (1999). The von Hippel–Lindau tumour suppressor protein: new perspectives. Molecular Medicine Today. 5(6). 257–263. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chi V. Dang Breakdown of academic impact, for papers by Victor E. Velculescu Breakdown of academic impact, for papers by Amato J. Giaccia Breakdown of academic impact, for papers by David Sidransky Breakdown of academic impact, for papers by Richard G. Pestell Breakdown of academic impact, for papers by Eric R. Fearon Breakdown of academic impact, for papers by Scott W. Lowe Breakdown of academic impact, for papers by Carlos Cordon‐Cardo Breakdown of academic impact, for papers by Mien‐Chie Hung Breakdown of academic impact, for papers by Kornélia Polyák
Rankless by CCL
2026